Targeted Therapies in the Treatment of Colorectal Cancers

Abstract

Background:

In solid organ malignancies, no tumor type has seen a greater impact from the development of novel targeted therapies in 2004 than metastatic colorectal cancer.

Methods:

We review the current progress to date with the use of monoclonal antibodies in colorectal cancer and look at newer therapies under investigation.

Results:

Two monoclonal antibodies received Food and Drug Administration approval in early 2004, both for the indication of advanced, metastatic colorectal cancer. A large, randomized, placebo-controlled study demonstrated that the addition of a monoclonal antibody to vascular endothelial growth factor, bevacizumab, led to a statistically significant improvement in overall survival, with tolerable additional toxicity. Chimeric monoclonal antibody therapy directed at the epidermal growth factor receptor was associated with radiographic responses in a significant minority of patients with irinotecan-refractory colon cancer in a randomized phase II study of patients with irinotecan-refractory disease.

Conclusions:

These dramatic successes have led to further clinical studies of targeted therapy in colorectal cancer, making it one of the most promising areas of cancer research.

References

Carpenter

, Chen

. Epidermal growth factor. J Biol Chem. 1990; 265: 7709–7712.

Salomon

D.S.

, Brandt

, Ciardiello

. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995; 19: 183–232.

Mayer

, Takimoto

, Fritz

. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor and mdr gene expression in colorectal cancer. Cancer. 1993; 71: 2454–2460.

Sato

J.D.

, Kawamoto

, Le

A.D.

. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med. 1983; 1: 511–529.

Mendelsohn

, Baselga

. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003; 21: 2787–2799.

Cunningham

, Humblet

, Siena

. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 7-22: 351: 337–345.

Saltz

, Rubin

, Hochster

. Cetuximab plus irinotecan is active in cpt-11-refractory colorectal cancer that expresses epidermal growth factor receptor. Proc Annu Meet Am Soc Clin Oncol. 2000; 22: A3531. Abstract.

Saltz

L.B.

, Meropol

N.J.

, Loehrer

Sr . Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004; 22: 1201–1208.

Common Toxicity Criteria for Adverse Events (CTCAE version 3). Available at: http://ctep.info.nih.gov/forms/CTCAEv3.pdf

10.

Badrinath

, Mitchell

E.P.

, Jennis

. Cetuximab plus FOLFOX for colorectal cancer: preliminary safety analysis of a randomized phase III trial. Proc Annu Meet Am Soc Clin Oncol. 2004; 22 (14S): A3531. Abstract.

11.

Lenz

H.J.

, Mayer

R.J.

, Gold

P.J.

. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proc Annu Meet Am Soc Clin Oncol. 2004; 22 (14S): A3510. Abstract.

12.

Chung

K.Y.

, Shia

, Kemeny

N.E.

. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005; 23: 1803–1810.

13.

Foon

K.A.

, Yang

X.D.

, Weiner

L.M.

. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys. 2004; 58: 984–990.

14.

Hecht

J.R.

, Patnaik

, Malik

A.I.

. ABX-EGF monotherapy in patients with metastatic colorectal cancer: an updated analysis. Proc Annu Meet Am Soc Clin Oncol. 2004; 22 (14S): A3511. Abstract.

15.

Sridhar

S.S.

, Seymour

, Shepherd

F.A.

. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol. 2003; 4: 397–406.

16.

Vanhoefer

, Tewes

, Rojo

. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol. 2004; 22: 175–184.

17.

Ciardiello

, Caputo

, Bianco

. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res. 2000; 6: 2053–2063.

18.

Rothenberg

M.L.

, Lafleur

, Washington

M.K.

. Changes in epidermal growth factor receptor signaling in serum and tumor biopsies obtained from patients with progressive metastatic colorectal cancer treated with gefitinib (ZD1839): an Eastern Cooperative Oncology Group study. Proc Annu Meet Am Soc Clin Oncol. 2004; 22 (14S): A3000. Abstract.

19.

Oza

A.M.

, Townsley

C.A.

, Siu

L.L.

. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Proc Annu Meet Am Soc Clin Oncol. 2003; 785. Abstract.

20.

McMahon

. VEGF receptor signaling in tumor angiogenesis. Oncologist. 2000; 5(Suppl 1): 3–10.

21.

Klagsbrun

, D'Amore

P.A.

. Vascular endothelial growth factor and its receptors. Cytokine Growth Factor Rev. 1996; 7: 259–270.

22.

Roberts

W.G.

, Palade

G.E.

. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci. 1995; 108: 2369–2379.

23.

Lee

J.C.

, Chow

N.H.

, Wang

S.T.

. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer. 2000; 36: 748–753.

24.

Choi

H.J.

, Hyun

M.S.

, Jung

G.J.

. Tumor angiogenesis as a prognostic predictor in colorectal carcinoma with special reference to mode of metastasis and recurrence. Oncology. 1998; 55: 575–581.

25.

Takahashi

, Kitadai

, Bucana

C.D.

. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995; 55: 3964–3968.

26.

Warren

R.S.

, Yuan

, Matli

M.R.

. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest. 1995; 95: 1789–1797.

27.

Presta

L.G.

, Chen

, O'Connor

S.J.

. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997; 57; 4593–4599.

28.

Fernando

N.H.

, Hurwitz

H.I.

. Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Oncologist. 2004; 9(Suppl 1): 11–18.

29.

Hurwitz

, Fehrenbacher

, Novotny

. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335–2342.

30.

Willett

C.G.

, Boucher

, di Tomaso

. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004; 10: 145–147.

31.

Giantonio

B.J.

, Catalano

P.J.

, Meropol

N.J.

. High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: results from the ECOG study E3200. Program and abstracts of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 27-29, 2005; Hollywood, Florida. Abstract 169A.

32.

Saltz

L.B.

, Lenz

H-J

, Kindler

. Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Program and abstracts of the American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 27-29, 2005; Hollywood, Florida. Abstract 169B.

33.

Wood

, Buchdunger

, Cozens

. Pharmacologic profile of a potent and orally active VEGF receptor kinases. Proc Annu Meet Am Soc Clin Oncol. 1998; 96. Abstract.

34.

Thomas

, Morgan

, Drevs

. Pharmacodynamic results using dynamic contrast enhanced magnetic resonance imaging of two phase 1 studies of the VEGF inhibitor PTK787/ZK 222584 in patients with liver metastases from colorectal cancer. Proc Annu Meet Am Soc Clin Oncol. 2001; 279. Abstract.

35.

Steward

W.P.

, Thomas

, Morgan

. Expanded phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer. Proc Annu Meet Am Soc Clin Oncol. 2004; 22 (14S): 3556A. Abstract.

36.

Schleucher

, Trarbach

, Junker

. Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer. Proc Annu Meet Am Soc Clin Oncol. 2004; 22 (14S): A3558. Abstract.

37.

Kobayashi

, Hande

K.R.

, Berlin

J.D.

. Phase I results of ABT-751, a novel microtubulin inhibitor, administered daily × 7 every 3 weeks. Proc Annu Meet Am Soc Clin Oncol. 2004; 22 (14S): A2079. Abstract.

38.

Cho

S.Y.

, Adamson

P.C.

, Hagey

A.E.

. Phase I trial and pharmacokinetic study of ABT-751, an orally bioavailable tubulin binding agent, in pediatric patients with refractory solid tumors. Proc Annu Meet Am Soc Clin Oncol. 2004; 22 (14S): A2080. Abstract.

39.

Garrett

, Dinwoodie

, Robert

. Phase I clinical studies of AG2037, a potent and novel inhibitor of glycinamide ribonucleotide formyltransferase. Proc Annu Meet Am Soc Clin Oncol. 2002; 429. Abstract.

40.

Syed

S.K.

, Beeram

, Takimoto

C.H.

. Phase I and pharmacokinetics (PK) of DJ-927, an oral taxane, in patients (Pts) with advanced cancers. Proc Annu Meet Am Soc Clin Oncol. 2004; 22 (14S): A2028. Abstract.

41.

Beeram

, Takimoto

C.H.

, Gadgeel

S.M.

. A phase I and pharmacokinetic (PK) study of DJ-927, an orally administered taxane, in patients with advanced malignancies. Proc Annu Meet Am Soc Clin Oncol. 2003; 524. Abstract.

42.

Holen

K.D.

, Syed

, Hannah

A.L.

. Phase I study using continuous intravenous (CI) KOS-862 (Epothilone D) in patients with solid tumors. Proc Annu Meet Am Soc Clin Oncol. 2004; 22 (14S): A2024. Abstract.

43.

Peng

, Hayes

, Resta

. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol. 2004; 22: 935–942.